Predictors for complete pathological response for stage II and III rectal cancer following neoadjuvant therapy - A systematic review and meta-analysis - 20/06/20
, Daniel Lee, BSc (Hons), MBBS a, b, Christopher Young, MBBS, MS, FRACS, FACS a, b, ⁎ 
Abstract |
Background |
There has been an increasing interest in the complete pathological response (pCR) in rectal cancers following neoadjuvant therapy. The aim of this study was to identify predictive factors of pCR in locally advanced rectal cancer following neoadjuvant therapy.
Methods |
The studies identified were appraised with standard selection criteria. The selection criteria included studies on patients with stage II or III rectal cancer who underwent neoadjuvant therapy.
Results |
Patients with pCR are more likely to be older (p = 0.0002), have cancers closer distance to the anal verge (p < 0.00001), smaller tumors (P < 0.0001), no clinical lymph nodes involvement (p=<0.00001) and waited more than eight weeks until definitive surgery (p = 0.002). There was no difference in gender (p = 0.15) and tumor differentiation (p = 0.21).
Conclusions |
The ‘Watch and Wait’ approach may be appropriate for selected patients. Patients with lower rectal cancers, smaller tumors, and negative clinical lymph node involvement may be more likely to achieve pCR following neoadjuvant therapy.
Le texte complet de cet article est disponible en PDF.Highlights |
• | There has been an interest in pCR after neoadjuvant therapy for rectal cancers. |
• | The ‘Watch and Wait’ approach may be appropriate for selected patients. |
• | Better prospective studies are warranted to establish the long-term outcomes. |
Keywords : Rectal cancer, Complete pathological response, Neoadjuvant therapy, Watch and wait approach
Plan
Vol 220 - N° 2
P. 300-308 - août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
